Devendra A.'s Colleagues at QED Therapeutics
Sam Casillas
Head of KOL Advocacy Development, Oncology/Rare Disease Marketing & Commercialization
Devendra A.'s Contact Details
HQ
650-231-4088
650-231-4088
Location
Company
QED Therapeutics
QED Therapeutics
Devendra A.'s Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Devendra A.
Devendra A. currently works for QED Therapeutics.
Devendra A.'s role at QED Therapeutics is Associate Director, Statistical Programming.
Devendra A.'s email address is ***@qedtx.com. To view Devendra A.'s full email address, please signup to ConnectPlex.
Devendra A. works in the Biotechnology industry.
Devendra A.'s colleagues at QED Therapeutics are Timothy Bisson, Quinn Nazarewycz, Jennifer Lai, Shivani Pandit, Chelsea Guiseppi, Sam Casillas, Deborah Mortensen and others.
Devendra A.'s phone number is 650-231-4088